These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24867835)

  • 1. The cost effectiveness of Botox in Italian patients with chronic migraine.
    Ruggeri M
    Neurol Sci; 2014 May; 35 Suppl 1():45-7. PubMed ID: 24867835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway.
    Hansson-Hedblom A; Axelsson I; Jacobson L; Tedroff J; Borgström F
    J Headache Pain; 2020 Aug; 21(1):99. PubMed ID: 32787820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK.
    Batty AJ; Hansen RN; Bloudek LM; Varon SF; Hayward EJ; Pennington BW; Lipton RB; Sullivan SD
    J Med Econ; 2013 Jul; 16(7):877-87. PubMed ID: 23647483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updated cost-effectiveness analysis of onabotulinumtoxinA for the prevention of headache in adults with chronic migraine who have previously received three or more preventive treatments in the UK.
    Hollier-Hann G; Curry A; Onishchenko K; Akehurst R; Ahmed F; Davies B; Keyzor I
    J Med Econ; 2020 Jan; 23(1):113-123. PubMed ID: 31578100
    [No Abstract]   [Full Text] [Related]  

  • 5. Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective.
    Lipton RB; Brennan A; Palmer S; Hatswell AJ; Porter JK; Sapra S; Villa G; Shah N; Tepper S; Dodick D
    J Med Econ; 2018 Jul; 21(7):666-675. PubMed ID: 29571276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Long-Term, Targeted OnabotulinumtoxinA versus Peripheral Trigger Site Deactivation Surgery for the Treatment of Refractory Migraine Headaches.
    Schoenbrunner AR; Khansa I; Janis JE
    Plast Reconstr Surg; 2020 Feb; 145(2):401e-406e. PubMed ID: 31985655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece.
    Giannouchos TV; Mitsikostas DD; Ohsfeldt RL; Vozikis A; Koufopoulou P
    Clin Drug Investig; 2019 Oct; 39(10):979-990. PubMed ID: 31302899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world economic impact of onabotulinumtoxinA in patients with chronic migraine.
    Rothrock JF; Bloudek LM; Houle TT; Andress-Rothrock D; Varon SF
    Headache; 2014; 54(10):1565-73. PubMed ID: 25298117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Onabotulinum toxin A (Botox) for chronic migraine treatment: an Italian experience.
    Grazzi L; Usai S
    Neurol Sci; 2015 May; 36 Suppl 1():33-5. PubMed ID: 26017508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of onabotulinumtoxinA (BOTOX(®)) for the management of urinary incontinence in adults with neurogenic detrusor overactivity: a UK perspective.
    Hamid R; Loveman C; Millen J; Globe D; Corbell C; Colayco D; Stanisic S; Gultyaev D
    Pharmacoeconomics; 2015 Apr; 33(4):381-93. PubMed ID: 25526842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales.
    Freemantle N; Khalaf K; Loveman C; Stanisic S; Gultyaev D; Lister J; Drake M
    Eur J Health Econ; 2016 Sep; 17(7):911-21. PubMed ID: 26482712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System.
    Bertapelle MP; Vottero M; Popolo GD; Mencarini M; Ostardo E; Spinelli M; Giannantoni A; D'Ausilio A
    World J Urol; 2015 Aug; 33(8):1109-17. PubMed ID: 25218855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK.
    Johnston K; Powell LC; Popoff E; L'Italien GJ; Pawinski R; Ahern A; Large S; Tran T; Jenkins A
    J Med Econ; 2024; 27(1):627-643. PubMed ID: 38590236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of onabotulinum toxin A (Botox(®)) in the treatment of chronic migraine at the Parma Headache Centre: a prospective observational study.
    Russo M; Manzoni GC; Taga A; Genovese A; Veronesi L; Pasquarella C; Sansebastiano GE; Torelli P
    Neurol Sci; 2016 Jul; 37(7):1127-31. PubMed ID: 27048312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Competing treatments for migraine: a headache for decision-makers.
    Mistry H; Naghdi S; Underwood M; Duncan C; Madan J; Matharu M
    J Headache Pain; 2023 Dec; 24(1):162. PubMed ID: 38053051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness Analysis of Anticholinergics Versus Botox for Urgency Urinary Incontinence: Results From the Anticholinergic Versus Botox Comparison Randomized Trial.
    Visco AG; Zyczynski H; Brubaker L; Nygaard I; Xu X; Lukacz ES; Paraiso MF; Greer J; Rahn DD; Meikle SF; Honeycutt AA
    Female Pelvic Med Reconstr Surg; 2016; 22(5):311-6. PubMed ID: 27564385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers.
    Tassorelli C; Aguggia M; De Tommaso M; Geppetti P; Grazzi L; Pini LA; Sarchielli P; Tedeschi G; Martelletti P; Cortelli P
    J Headache Pain; 2017 Dec; 18(1):66. PubMed ID: 28667550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting.
    Kollewe K; Escher CM; Wulff DU; Fathi D; Paracka L; Mohammadi B; Karst M; Dressler D
    J Neural Transm (Vienna); 2016 May; 123(5):533-40. PubMed ID: 27032774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness and cost-utility of the treatment of chronic hepatitis B with peginterferon alfa-2a, interferon alfa, and lamivudine in Lithuania.
    Vanagas G; Padaiga Z; Mickevičienė A
    Medicina (Kaunas); 2010; 46(12):835-42. PubMed ID: 21532288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for use of onabotulinum toxin A (BOTOX) in chronic migraine.
    Barbanti P; Egeo G; Fofi L; Aurilia C; Piroso S
    Neurol Sci; 2015 May; 36 Suppl 1():29-32. PubMed ID: 26017507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.